16 September 2026 editorial review · Trial
Semaglutide to reduce carb-counting burden on closed loop: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: M–S
Outcome: Corrected2×4 to registered2×3 crossover factorial design; supplied eligibility and distinguished glycemic adjunct from regeneration. Corrected direct item relationships; shared class or background is insufficient.
Registry: NCT06387199. Endpoint reviewed: Percentage of daytime plasma glucose levels spent in target range (semaglutide vs. placebo) (24 weeks). Eligibility reviewed: Age unspecified to unspecified; diagnosis/stage, prior therapy and key biomarker criteria compared with site summary. Full exclusions remain in the registry. Literature access limit: No usable primary abstract was independently recovered for this record in this pass. Current registry protocol was the main source; detailed sponsor or conference data remain dependent on the cited source and were not fully reverified.